ABOUT UCERIS TABLETS
UCERIS tablets with MMX® technology: Extended release of budesonide in the colon1
- UCERIS tablets contain budesonide—a steroid with high topical activity
- Topical potency 15x that of prednisolone, the active metabolite of prednisone
- Budesonide has up to 90% first-pass metabolism
- In clinical trials, overall glucocorticoid effects were similar to placebo over the 8 weeks of induction therapy
Caution should be taken in patients with hypertension, diabetes mellitus, osteoporosis, peptic ulcer, glaucoma or cataracts, or with a family history of diabetes or glaucoma, or with any other condition where glucocorticosteroids may have unwanted effects.
UCERIS tablets use MMX® technology.2 The tablets are enteric coated to prevent dissolution in the stomach, and do not dissolve until they reach pH ≥7 in the terminal ileum of the small intestine.1,3
After reaching the colon, the tablet matrix expands, providing extended release of budesonide in a time-dependent manner.1 UCERIS tablets have been detected by scintigraphic imaging in the ascending colon between 4 and 24 hours after dosing.3
The clinical effect of drug delivery on outcome is unknown.
UCERIS tablets with MMX® technology provide extended release of budesonide in the colon, in a time-dependent manner.1,3
UCERIS is a single 9-mg tablet taken once daily in the morning by mouth for up to 8 weeks.1
SELECTED IMPORTANT SAFETY INFORMATION
- UCERIS extended release tablets are contraindicated in patients with hypersensitivity to budesonide or any of the ingredients of UCERIS tablets. Anaphylactic reactions have occurred with other budesonide formulations
- Care is needed in patients who are transferred from glucocorticosteroid treatment with higher systemic effects to glucocorticosteroids with lower systemic effects, such as UCERIS tablets, since symptoms attributed to withdrawal of steroid therapy, including those of acute adrenal suppression or benign intracranial hypertension, may develop. Adrenocortical function monitoring may be required in these patients. Taper patients slowly from systemic corticosteroids if transferring to UCERIS tablets